A detailed history of Rhumbline Advisers transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 49,868 shares of URGN stock, worth $642,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,868
Previous 50,477 1.21%
Holding current value
$642,299
Previous $847,000 25.27%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$12.7 - $17.92 $7,734 - $10,913
-609 Reduced 1.21%
49,868 $633,000
Q2 2024

Aug 01, 2024

BUY
$12.72 - $19.2 $174,022 - $262,675
13,681 Added 37.18%
50,477 $847,000
Q1 2024

May 09, 2024

BUY
$13.81 - $19.33 $28,862 - $40,399
2,090 Added 6.02%
36,796 $551,000
Q4 2023

Feb 08, 2024

BUY
$10.87 - $15.93 $85,242 - $124,923
7,842 Added 29.19%
34,706 $520,000
Q3 2023

Nov 09, 2023

BUY
$8.84 - $22.64 $57,088 - $146,209
6,458 Added 31.65%
26,864 $376,000
Q2 2023

Aug 08, 2023

BUY
$8.75 - $14.29 $178,552 - $291,601
20,406 New
20,406 $211,000
Q2 2022

Aug 11, 2022

SELL
$5.12 - $8.74 $118,538 - $202,348
-23,152 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$5.92 - $9.73 $5,399 - $8,873
-912 Reduced 3.79%
23,152 $202,000
Q4 2021

Feb 10, 2022

SELL
$9.03 - $19.13 $3,106 - $6,580
-344 Reduced 1.41%
24,064 $229,000
Q3 2021

Nov 12, 2021

BUY
$14.31 - $18.39 $7,226 - $9,286
505 Added 2.11%
24,408 $411,000
Q2 2021

Aug 05, 2021

SELL
$15.2 - $20.94 $40,660 - $56,014
-2,675 Reduced 10.06%
23,903 $365,000
Q1 2021

May 06, 2021

SELL
$17.99 - $26.96 $37,239 - $55,807
-2,070 Reduced 7.23%
26,578 $518,000
Q4 2020

Feb 10, 2021

BUY
$17.54 - $25.43 $54,917 - $79,621
3,131 Added 12.27%
28,648 $516,000
Q3 2020

Nov 12, 2020

SELL
$18.81 - $26.42 $67,151 - $94,319
-3,570 Reduced 12.27%
25,517 $492,000
Q2 2020

Aug 13, 2020

BUY
$16.5 - $29.7 $91,393 - $164,508
5,539 Added 23.52%
29,087 $760,000
Q1 2020

May 06, 2020

BUY
$13.68 - $34.6 $1,956 - $4,947
143 Added 0.61%
23,548 $420,000
Q4 2019

Feb 05, 2020

BUY
$21.11 - $34.86 $29,448 - $48,629
1,395 Added 6.34%
23,405 $781,000
Q3 2019

Oct 23, 2019

BUY
$23.83 - $36.44 $22,185 - $33,925
931 Added 4.42%
22,010 $524,000
Q2 2019

Aug 14, 2019

BUY
$32.75 - $40.35 $690,337 - $850,537
21,079 New
21,079 $758,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $293M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.